FOR IMMEDIATE RELEASE
Sr. Director Brand Marketing North America
Luneau Technology USA
1 (800) 729-1959
Reintroducing Visionix — Luneau Technology launches as “Visionix” to manufacture and sell Optovue, Visionix, Briot and Weco brands
Visionix unveils its new identity and showcases an expanded suite of advanced visual health solutions at VEE 2022, Optovue Inc. becomes a product brand for its OCT line
Bensenville, IL: : Luneau Technology Group recently announced that it will take on “Visionix” as its official global name beginning March 31, 2022, unveiling a combined booth at Vision Expo East. As mentioned in the recent global announcement, “Optovue” will transition to a product brand for Visionix’s OCT and OCTA line.
A global brand transition
Headquartered in France, Visionix is a world-class player in visual healthcare. The company develops, manufactures, and markets ophthalmic equipment from refraction and multimodal diagnostic devices; to lens finishing equipment. The Visionix brand comprises the formerly individual brands of Luneau Technology, Briot (finishing), Weco (finishing), Visionix (diagnosis and refraction), Next Sight (fundus camera and telehealth solutions) and Optovue (high-speed OCT and OCTA technology). The new Visionix company will be the global sales, service, and training provider for all product brands, integrating core refractive, screening, and imaging technologies to address the needs of eye care professionals.
The Visionix product line, the company’s flagship brand, was founded by CEO and President Marc Abitbol Ph.D. in1994 as a research and development lab for applications in wavefront-based technology. Within the last three decades, the company has expanded its range of offerings with the addition of other specialty brands like Briot and Weco (acquired in 2010) and Optovue (merged in 2021).
Today, the group has 700 employees in 120 countries, and offers a wide range of products. “We have grown our business significantly over the past several years, and our new brand reflects that transformation,” said Dr. Abitbol. “Our new identity is innovative, modern, and professional—words we use to describe who we are as an organization but also the technology solutions we provide to our customers who want to expand their business.” Dr. Abitbol added, “Today, Visionix offers an integrated range of multimodal products primarily serving eye care professionals. Our ambition is to be a world-class leader and the first choice for helping providers simplify their patients’ access to visual health.”
North America: What is changing?
North America is a primary focus of the new group. There are fewer than 700,000 eye care professionals globally for a 7.2 billion population, resulting in delayed access to ophthalmic care. Automated and integrated Visionix technologies were designed to assist in closing this gap and to help practices grow and serve more patients.
As a result of the merger with Optovue, the North American organization tripled its team of field representatives for Sales, Service, and Clinical Application, introducing more specialized professionals to consult with ECPs throughout the buying process and beyond. Dan McNulty continues to lead the expanded team as President for its commercial organization in North America.
According to McNulty, “Our goal has been and will always be to improve access to forward-thinking technology that transforms the patient experience. The addition of Optovue into our range of offerings for the medical eye care market makes us an ideal partner because we are uniquely positioned to provide a complete end-to-end solution in retail, refraction, and medical markets for primary eye care.”
Visionix: New technology to help Practitioners detect a range of eye health symptoms
For the first time at Vision Expo East, Visionix will introduce a remote-ready refraction and screening technology suite integrating its most advanced multi-modal devices. The next-generation Visionix platforms offer varying levels of patient data integration, and the most advanced solutions offer multiple test functionalities in a single device—providing all necessary data for a comprehensive exam with significantly less patient movement from instrument to instrument.
The second-generation Eye Refract is a highly automated and dynamic binocular, wavefront-based refraction system that includes a digital acuity short chart and the VX40 lens analyzer.
The newest addition to its multi-modal screening line is VX650 which combines a 45-degree fundus camera with a plethora of technologies in one single device, including: Shack-Hartmann Wavefront based anterior segment analysis, including Autorefraction/ Keratometry, Placido Ring Corneal Topography, Anterior/Posterior Corneal Tomography, Aberrometry, Retro-Illumination, Anterior Chamber Analysis, Pachymetry, Scheimpflug Imaging, and Non-Contact Tonometry.
VX650 integrates seamlessly with the compact Eye Refract and can be placed on a single tabletop or set up separately in a five square feet pre-test room, offering a complete suite with a small footprint. The optional table’s ergonomic design even allows a wheelchair to fit comfortably, an excellent benefit for practitioners who see patients with mobility issues.
Optovue: An OCT and OCTA for every practice
The company will be unveiling its expanded product line at Vision Expo East, with a wide range of OCT technology alongside its screening, refraction, and optical brands. The Optovue line offers high-speed OCT and OCT-A technology to equip providers with the best imaging tools to diagnose and manage eye diseases. The company’s most advanced solution today is the Optovue Avanti® Widefield OCT which offers state-of-the-art imaging from the cornea to the choroid with exclusive technology that will change your approach to disease diagnosis and management.
ECPs can add Optovue AngioVue® OCT Angiography (OCTA) to the Avanti platform to bring non-invasive vascular imaging with measurement tools to your practice. Practices can ease into OCTA with AngioVue Essential or choose AngioVue Comprehensive to access all available OCTA features.
Briot and Weco: Continuing a legacy in Optical innovation
The company’s legacy brands, Weco and Briot, were established in 1913 and 1936, respectively; and continue to be the leading brands in finishing technology platforms for Optical and Retail practices. Briot® Couture, its newest edger initially unveiled at Vision Expo West 2021, makes its debut at Vision Expo East. It is a highly intuitive finishing solution for any Optical that combines an edger with a state-of-the-art tracer-blocker unit.
Inspired by the popular Briot® Attitude edger, Couture is the first finishing platform that is powered by virtual 3D rendering technology, allowing Opticians to visualize the final output before edging. A range of finishing technologies will be available for a live demo and ROI consultation at Vision Expo East.
ECPs can experience the new products firsthand by requesting a live demo or scheduling a virtual demo with a Clinical and Optical Specialist. These new technologies aim to transform and improve access to all patients in the United States and Canada and help preserve their visual health. To learn more, visit http://www.visionix.com/demo
For more information about the global announcement, contact Lionel Iribarne, email@example.com, +33 (0)6 45 75 03 88 Read more at www.visionix.com
About Visionix North America
Visionix North America, formerly Luneau Technology | Optovue, is the global manufacturer and exclusive sales, service, and training provider for Optovue®, Visionix®, Briot® and Weco® brands in the United States and Canada. We are the pioneer in integrating core refractive, screening, and imaging technologies to address the ever-changing needs of eye care professionals in this dynamic market. Today, we are proud to offer high-speed OCT and OCTA technology designed to facilitate diagnosing and managing a range of ocular diseases. Our goal is to improve access to a complete suite of advanced visual health solutions that transforms the patient experience. With over 100 years of innovation, an expanded product line, as well as a new level of support, clinical education, and practice integration, we are well-positioned to help you unlock your potential. Read more at www.visionix.com